Endpoints News 2025-12-06 #ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
Endpoints News 2025-12-06 #ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens
Endpoints News 2025-12-06 Apple Tree Partners scores legal win against alleged holdout Russian investor
Endpoints News 2025-12-06 ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more
Endpoints News 2025-12-06 ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations
Endpoints News 2025-12-05 Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara
Endpoints News 2025-12-05 OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio
Endpoints News 2025-12-05 German court stops Merck from selling subcutaneous Keytruda in patent battle with Halozyme
Endpoints News 2025-12-05 Ex-Intercept CEO takes over at Altimmune; Carolyn Bertozzi leaves Alnylam's board
Endpoints News 2025-12-04 Trump administration pushes end-of-term deadline for ‘most favored nation’ promises
Endpoints News 2025-12-04 UniQure restates FDA's negative feedback on Huntington's trial; Neurimmune's expanded AstraZeneca alliance